PDCD1 and metastatic malignant neoplasm: For patients with metastatic cancer treated with PD-1 blockade, MSI and high mutation burden in pretreatment plasma-predicted progression-free survival and longitudinal analysis of MSI sequencing led to the identification of patients with a durable response to PD-1 blockade.